Rapid Resolution of Obsessions After an Infusion of Intravenous Ketamine in a Patient With Treatment-Resistant Obsessive-Compulsive Disorder
Open accessAbstract
Article AbstractLetter to the Editor Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.To the Editor: Obsessive-compulsive disorder (OCD) is a leading cause of illness-related disability. Identifying more effective treatments with faster onset of action would be a major advance. Medications thought to modulate the glutamate system are promising new agents; for example, open trials of riluzole, memantine, and minocycline as augmentation to serotonin reuptake inhibitors (SRIs) suggest that up to half of OCD patients may experience reductions in symptoms.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
An early randomized controlled trial (n=15) and a case report found ketamine effectively targeted obsessions and compulsions characteristic of OCD, as measured by Y-BOCS.
“An early, randomized, controlled trial (n = 15) and a case report both found that ketamine effectively targeted the obsessions and compulsions characteristic of OCD, as measured by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) [108,109]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [109]
The Case report describes one patient's obsessions ceasing during ketamine infusion, supporting the case-report portion of the claim. It says changes were assessed with the OCD-VAS, focusing on obsessions rather than compulsions; Y-BOCS was reported only at baseline. This source does not establish that ketamine reduced both obsessions and compulsions as measured by Y-BOCS. (LLM, conf=0.90)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · see citing works
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · see citing works
(1996) · Cited by 6,884 · see citing works
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · see citing works
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · see citing works
The Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799 · see citing works
Ostwald, P. F. (1960) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1960.14.4.817 · Cited by 1,422 · see citing works
Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice
Welch, J. M., Lu, J., Rodriguiz, R. M., Trotta, N. C., Peca, J., Ding, J.-D., Feliciano, C., Chen, M., Adams, J. P., Luo, J., et al. (2007) · Nature · doi:10.1038/nature06104 · Cited by 852 · see citing works
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · see citing works
Mechanism of action of memantine
Johnson, J. M., & Kotermanski, S. E. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.09.007 · Cited by 500 · see citing works
Brief Psychiatric Rating Scale
Overall, J. E., & Gorham, D. R. (1962) · PsycTESTS Dataset · doi:10.1037/t01554-000 · Cited by 498 · see citing works
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314 · see citing works
Murphy, D. L., Mueller, E. A., Hill, J., Tolliver, T. J., & Jacobsen, F. M. (1989) · Psychopharmacology · doi:10.1007/bf00444705 · Cited by 201 · see citing works
Lafleur, D. L., Pittenger, C., Kelmendi, B., Gardner, T., Wasylink, S., Malison, R. T., Sanacora, G., Krystal, J. H., & Coric, V. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0246-6 · Cited by 200 · see citing works
A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder
Stewart, S. E., Jenike, E. A., Hezel, D. M., Stack, D. E., Dodman, N. H., Shuster, L., & Jenike, M. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c856de · Cited by 158 · see citing works
Memantine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder
Aboujaoude, E. N., Barry, J. J., & Gamel, N. N. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318192e9a4 · Cited by 137 · see citing works
Feusner, J. D., Kerwin, L. E., Saxena, S., & Bystritsky, A. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4096 · Cited by 91 · see citing works
Abrantes, A. M., Strong, D. R., Cohn, A., Cameron, A. Y., Greenberg, B. D., Mancebo, M. C., & Brown, R. A. (2009) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2009.06.008 · Cited by 73 · see citing works
Minocycline Augmentation of Pharmacotherapy in Obsessive-Compulsive Disorder
Rodríguez, C. I., Bender, J., Marcus, S. M., Snape, M. F., Rynn, M. A., & Simpson, H. B. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09l05805blu · Cited by 56 · see citing works
Self-citationYoung, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. (1978) · PsycTESTS Dataset · doi:10.1037/t20936-000 · Cited by 54 · see citing works
Greenberg, B. D., Benjamin, J., Martin, J. D., Keuler, D. J., Huang, S. ‐., Altemus, M. M., & Murphy, D. L. (1998) · Psychopharmacology · doi:10.1007/s002130050787 · Cited by 35 · see citing works
A Randomized Trial of an N-methyl-d-aspartate Antagonist in Treatment-Resistant Major Depression
Ballenger, J. C. (2008) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70782-5 · Cited by 5 · see citing works
Flagged first, then by citations
1 of the 23 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426 · see citing works
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386 · see citing works
Self-citationPharmacological treatment of anxiety disorders: Current treatments and future directions
Farach, F. J., Pruitt, L. D., Jun, J. J., Jerud, A. B., Zoellner, L. A., & Roy‐Byrne, P. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2012.07.009 · Cited by 183 · see citing works
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Bloch, M. H., Wasylink, S., Landeros-Weisenberger, A., Panza, K. E., Billingslea, E., Leckman, J. F., Krystal, J. H., Bhagwagar, Z., Sanacora, G., & Pittenger, C. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.028 · Cited by 162 · see citing works
Fineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161 · see citing works
An update on ketamine and its two enantiomers as rapid-acting antidepressants
Zhang, K., & Hashimoto, K. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1554434 · Cited by 132 · see citing works
Martinotti, G., Chiappini, S., Pettorruso, M., Mosca, A., Miuli, A., Carlo, F. D., d’Andrea, G., Collevecchio, R., Muzio, I. D., Sensi, S. L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11070856 · Cited by 114 · see citing works
Murphy, D. L., Moya, P. R., Fox, M. A., Rubenstein, L. M., Wendland, J. R., & Timpano, K. R. (2013) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2012.0435 · Cited by 107 · see citing works
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108 · see citing works
Treatment-resistant OCD: Pharmacotherapies in adults
van Roessel, P., Grassi, G., Aboujaoude, E. N., Menchón, J. M., Ameringen, M. V., & Rodríguez, C. I. (2022) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2022.152352 · Cited by 91 · see citing works
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83 · see citing works
Acute effects of cannabinoids on symptoms of obsessive‐compulsive disorder: A human laboratory study
Kayser, R. R., Haney, M., Raskin, M., Arout, C. A., & Simpson, H. B. (2020) · Depression and Anxiety · doi:10.1002/da.23032 · Cited by 85 · see citing works
Self-citationCan Exposure-Based CBT Extend the Effects of Intravenous Ketamine in Obsessive-Compulsive Disorder?
Rodríguez, C. I., Wheaton, M. G., Zwerling, J., Steinman, S. A., Sonnenfeld, D., Galfalvy, H., & Simpson, H. B. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15l10138 · Cited by 63 · see citing works
Self-citationRodríguez, C. I., Kegeles, L. S., Levinson, A. R., Ogden, R. T., Mao, X., Milak, M. S., Vermes, D., Xie, S., Hunter, L. E., Flood, P. D., et al. (2015) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2015.06.001 · Cited by 61 · see citing works
Self-citationWhittaker, E., Dadabayev, A. R., Joshi, S. A., & Glue, P. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211056743 · Cited by 56 · see citing works
Glutamatergic agents for OCD and related disorders
Pittenger, C. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0051-8 · Cited by 62 · see citing works
Pharmacotherapeutic Strategies and New Targets in OCD
Pittenger, C. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_204 · Cited by 51 · see citing works
Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach
Grados, M. A., Specht, M. W., Sung, H.-M., & Fortune, D. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.845553 · Cited by 49 · see citing works
Kohtala, S., Alitalo, O., Rosenholm, M., Rozov, S. V., & Rantamäki, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107741 · Cited by 46 · see citing works
Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder
Grassi, G., Cecchelli, C., Vignozzi, L., & Pacini, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s255375 · Cited by 44 · see citing works
Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review
Bandeira, I. D., Lins-Silva, D. H., Cavenaghi, V. B., Dorea-Bandeira, I., Faria-Guimarães, D., Barouh, J. L., Jesus-Nunes, A. P., Beanes, G., Souza, L. S., Leal, G. C., et al. (2022) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000330 · Cited by 39 · see citing works
Grados, M. A., Atkins, E., Kovacikova, G. I., & McVicar, E. L. (2015) · Psychology Research and Behavior Management · doi:10.2147/prbm.s58601 · Cited by 39 · see citing works
Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications
Vlček, P., Polák, J., Brunovský, M., & Horáček, J. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-118665 · Cited by 30 · see citing works
Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept
Rodríguez, C. I., Zwerling, J., Kalanthroff, E., Shen, H., Filippou-Frye, M., Jo, B., Simpson, H. B., Burch, R. M., & Moskal, J. R. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16080868 · Cited by 27 · see citing works
Self-citationCurrent and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults
Grassi, G., & Pallanti, S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528230 · Cited by 25 · see citing works
Challenges in Testing Intranasal Ketamine in Obsessive-Compulsive Disorder
Rodríguez, C. I., Lapidus, K. A. B., Zwerling, J., Levinson, A. R., Mahnke, A., Steinman, S. A., Kalanthroff, E., & Simpson, H. B. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16cr11234 · Cited by 25 · see citing works
Self-citationMowla, A., & Ghaedsharaf, M. (2019) · CNS Spectrums · doi:10.1017/s1092852919001500 · Cited by 25 · see citing works
A transdiagnostic systematic review and meta-analysis of ketamine’s anxiolytic effects
Hartland, H., Mahdavi, K., Jelen, L. A., Strawbridge, R., Young, A. H., & Alexander, L. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231161627 · Cited by 28 · see citing works
Pittenger, C., Brennan, B. P., Koran, L. M., Mathews, C. A., Nestadt, G., Pato, M. T., Phillips, K. A., Rodríguez, C. I., Simpson, H. B., Skapinakis, P., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113853 · Cited by 22 · see citing works
Self-citationN-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: A case series
van Ameringen, M. V., Patterson, B., Simpson, W., & Turna, J. (2013) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2012.10.003 · Cited by 22 · see citing works
The Glutamate and the Immune Systems: New Targets for the Pharmacological Treatment of OCD
Marazziti, D., Albert, U., Mucci, F., & Piccinni, A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666171108152035 · Cited by 19 · see citing works
Marcatili, M., Pellicioli, C., Maggioni, L., Motta, F. L., Chiara, R., Lorenzo, G., Michaela, K., Sibilla, M., Nava, R., Colmegna, F., et al. (2021) · Annals of General Psychiatry · doi:10.1186/s12991-021-00365-z · Cited by 14 · see citing works
Kayser, R. R., Senter, M. S., Tobet, R., Raskin, M., Patel, S. R., & Simpson, H. B. (2021) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2021.100664 · Cited by 12 · see citing works
Self-citationFerguson, A. A., Khan, A. I., Abuzainah, B., Chaudhuri, D., Khan, K. I., Shouli, R. A., Allakky, A., & Hamdan, J. A. (2023) · Cureus · doi:10.7759/cureus.37833 · Cited by 10 · see citing works
Alves-Pereira, R., Fontes, M., Cordeiro, V., Bandeira, I. D., Faria-Guimarães, D., Silva, S. S., Mello, R. P., Leal, G. C.-G., Sampaio, A. S., & Quarantini, L. C. (2024) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000578 · Cited by 9 · see citing works
Ameringen, M. V., Fineberg, N. A., Ravindran, A. V., Arnold, P. D., Beaulieu, S., Brakoulias, V., Brietzke, E. M., Dowlati, Y., Drummond, L. M., Ferretti, C. J., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.12.039 · Cited by 10 · see citing works
Abdel-Ahad, P., & Kazour, F. (2015) · Current Clinical Pharmacology · doi:10.2174/15748847113089990060 · Cited by 9 · see citing works
Kaltenboeck, A., Foerster, E., Strafner, S., Demal, U., Mossaheb, N., & Friedrich, F. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1291077 · Cited by 8 · see citing works
Grassi, G., Scillitani, E., & Cecchelli, C. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2387127 · Cited by 8 · see citing works
Psychothérapie augmentée par la kétamine (KAP) dans les troubles de l’humeur : mode d’emploi
Bottemanne, H., Baldacci, A., Muller, C., Boyreau, A., & Claret, A. (2021) · L Encéphale · doi:10.1016/j.encep.2021.08.011 · Cited by 8 · see citing works
Ayub, J. G. M., Tosta, C. L., Macedo, B. L., Barreto, T. F., Lopes, L. M., Fracalossi, M. P. D. S., Andreatini, R., & Beijamini, V. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175382 · Cited by 6 · see citing works
Köse, S., & Çetin, M. (2017) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2017.1357355 · Cited by 4 · see citing works
Algin, S., Banik, D., Rahman, S. A., Tusher, S. M., Johora, F. T., Akter, A., Ahmed, T., Biswas, M. A. M., Sinha, S., & Haque, M. (2024) · Cureus · doi:10.7759/cureus.57877 · Cited by 3 · see citing works
Kumar, S., Pattnaik, J. I., Panda, U. K., Dixit, T., Srivastava, A., Pal, S., Acharya, B., Gulati, M., & Ravan, J. R. (2025) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry_1144_24 · Cited by 3 · see citing works
Avances en el tratamiento farmacológico del trastorno obsesivo-compulsivo.
Vega‐Dienstmaier, J. M. (2017) · Revista de Neuro-Psiquiatría · doi:10.20453/rnp.v79i4.2978 · Cited by 3 · see citing works
Marmureanu, M., Besoiu, M. V., Dionisie, V., Manea, M. C., Pleșea-Condratovici, C., Voican, S. I., & Manea, M. (2026) · Pharmaceuticals · doi:10.3390/ph19040628 · Cited by 2 · see citing works
Bottemanne, H., Arnould, A., Najar, A., Delaigue, F., Serresse, L., Joly, L., & Mouchabac, S. (2023) · L Encéphale · doi:10.1016/j.encep.2022.08.011 · Cited by 2 · see citing works
Yount, S. T., Wang, S., Allen, A. T., Shapiro, L. P., Butkovich, L. M., & Gourley, S. L. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102632 · Cited by 2 · see citing works
An Examination of the Effectiveness of SSRIs with clomipramine on OCD Patients
Skoutas, E. (2024) · Journal of Student Research · doi:10.47611/jsr.v13i1.2417 · Cited by 1 · see citing works
Emerging Data for Ketamine in Obsessive-Compulsive, Stress-Related, and Substance Use Disorders
Rodríguez, C. I., & Dakwar, E. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_9
Beyond Depression: Ketamine and Glutamatergic Agents for PTSD, OCD, and Other Potential Applications
Dougherty, J. W., Ettensohn, M. F., & Levine, S. P. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180312-03
(2017) · Reactions Weekly · doi:10.1007/s40278-017-25745-9
Chapter 52. Treatment of Obsessive-Compulsive Disorder
Kayser, R. R., & Simpson, H. B. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as52 · Cited by 1 · see citing works
Self-citationVoderholzer, U., Rubart, A., Kathmann, N., Staniloiu, A., Kordon, A., & Zurowski, B. (2024) · Springer eBooks · doi:10.1007/978-3-662-67878-7_6
Prescribing in Children and Adolescents
(2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg005.pub2
Angel, M. (2026) · Case Reports in Psychiatry · doi:10.1155/crps/6450306
Eghdami, S., Boroon, M., Keshavarz‐Akhlaghi, A., & Shalbafan, M. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07155-z
Barlattani, T., Sernia, G., D’Amelio, C., Maritato, S., Gabriele, D., Bologna, A., Trebbi, F., Ricci, V., Tomasetti, C., Martiadis, V., et al. (2026) · Psychiatry International · doi:10.3390/psychiatryint7050207
Ketamine Augmentation of Exposure Response Prevention Therapy for Obsessive Compulsive Disorder
Bottemanne, H., & Arnould, A. (2021) · Unpublished · doi:10.13140/rg.2.2.33281.48485 · Cited by 8 · see citing works
- Authors
- Rodriguez, C. I., Kegeles, L. S., Flood, P., & Simpson, H. B.
- Affiliations
- Columbia University (US)
- New York State Psychiatric Institute (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2011-04-15
- Volume
- 72
- Issue
- 04
- Pages
- 567-569
- ISSN
- 0160-6689 (ISSN-L)
- PMC
- PMC3727240
- OpenAlex
- W2070440162
- Cited by
- 59
- References
- 23
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 7 · 2023: 5 · 2022: 3 · 2021: 9 · 2020: 3 · 2019: 1 · 2018: 4 · 2017: 6 · 2016: 3 · 2015: 4 · 2013: 3 · 2012: 3
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (MH015144, K23MH092434, T32MH015144)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- obsessive-compulsive disorder, treatment-resistant OCD, ketamine, intravenous infusion, obsession, glutamate modulation, augmentation therapy
- MeSH terms
- Double-Blind Method, Female, Humans, Infusions, Intravenous, Ketamine, Obsessive-Compulsive Disorder, Psychiatric Status Rating Scales, Excitatory Amino Acid Antagonists, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
